Key Findings:  Study results demonstrate for the first time that both GPR3 and GPR6 are novel molecular targets for CBD. This discovery that CBD acts as a novel inverse agonist on both GPR3 and GPR6 indicates that some of the potential therapeutic effects of CBD (e.g. treatment of Alzheimer's disease and Parkinson's disease) may be mediated through these important receptors.
Type of Study:  Laboratory Study
Study Result:  Positive
Cannabinoids Studied:  Cannabidiol (CBD)
Phytocannabinoid Source:  Not Applicable
Chemotype:  Chemotype III